Thomas Helleday Foundation Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2017
NCT03036228
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Thomas Helleday Foundation

Active Ingredients

Drugs in Phase 1 Trials (1)

karonudib (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1